Diabetes patients likely to develop macula oedema after cataract surgery

Article

Patients with Type 2 diabetes undergoing cataract surgery are twice as likely to develop macula oedema than patients without diabetes.

Patients with Type 2 diabetes undergoing cataract surgery are twice as likely to develop macula oedema than patients without diabetes, according to Anna Wikberg-Matsson and colleagues from Uppsala University, Sweden.

A consecutive, prospective, randomized study followed two groups of patients, 40 with simplex retinopathy and 40 healthy patients, after cataract surgery. Preoperative visual acuity (VA) in the diabetes group was 0.4 and 0.5 in the control group.

At six-weeks follow-up, the VA was 0.5 and 0.8 in the diabetes and the control group, respectively whilst at six months the VA was 0.77 and 0.9, respectively. Macula oedema was seen in 77% of the diabetes patients at the six-week time point and in 30% of the controls. At six weeks, macula volume had increased in both groups but there was a significant difference between the two groups (p<0.05).

It was concluded by the researchers that patients with Type 2 diabetes are twice as likely to develop macula oedema following cataract surgery than healthy subjects.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.